When was Celularity founded?

Celularity was founded in 2016 and raised its 1st funding round 1 year after it was founded.

Where is Celularity located?

Celularity is headquartered in Warren, United States. It is registered at Warren, New Jersey.

How many employees does Celularity have?

As of Jun 30, 2026, the latest employee count at Celularity is 145.

Is Celularity a funded company?

Celularity is a funded company, having raised a total of $290M across 7 funding rounds to date. The company's 1st funding round was a $40M Series C round, raised on Aug 15, 2017.

When was the latest funding round of Celularity?

Celularity's latest funding was a $10M Post IPO round on Dec 22, 2025, with participation from 0 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $2.85B in funding in 2026 to date.

What is the annual revenue of Celularity?

Annual revenue of Celularity is between $50M and $100M as on Dec 31, 2024

Is Celularity a Oncology company?

The primary sector of Celularity is Oncology.

Where does Celularity rank among its competitors?

Celularity ranks 16th amongst 3273 active competitors, of which 1116 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Celularity?

Celularity's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Celularity - 2026 Company Profile, Funding, Competitors & Financials

Celularity is a public company based in Warren (United States), founded in 2016. It operates as a Developer of allogeneic cell therapies to treat multiple diseases. Celularity has raised $290M in funding from Celgene. The company has 3273 active competitors, including 1116 funded and 774 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Sectors and market segments that Celularity operate in

Celularity serves in the Life Sciences market segments.The primary business model of Celularity is:

Life Sciences > Oncology > ***** **** > ***** ******

Company Details

Developer of allogeneic cell therapies to treat multiple diseases. The company focuses on placenta-derived cell therapy product candidates for cancer, infectious diseases, and degenerative diseases. The company's lead candidate is CYNK001 for acute myeloid leukemia and Glioblastoma.

Website: celularity.com
Social
Registered Address: Warren, New Jersey

Key Metrics

Founded Year

2016

Location

Warren, United States

Stage

Public

Total Funding

$290M in 7 rounds

Latest Funding Round

Post IPO, Dec 22, 2025, $10M

Investors

Celgene & 9 more

Ranked

16^th among 3273 active competitors

Annual Revenue

$50M - $100M as on Dec 31, 2024

Employee Count

145 as on Jun 30, 2026

Investment & Acquisitions

CariCord

Similar Companies

Jazz Pharmaceuticals & 2975 more

Exit Details

Public

View Celularity's full profile

Celularity is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
GX ACQUISITION CORP. CIN: 1752828 , United States, Active		$50M - $100M (As on Dec 31, 2024)	-	-
Celularity, Inc. CIN: 813931841 , United States, Active	Dec 31, 1999	$10M - $50M (As on Dec 31, 2022)	227 (As on Dec 31, 2021)	-

Celularity got listed on Aug 08, 2019.

Click here to take a look at Celularity's IPO in detail

Celularity has raised a total funding of $290M over 7 rounds. Its first funding round was on Aug 15, 2017. Celularity has 10 institutional investors.

Here is the list of recent funding rounds of Celularity:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 22, 2025	$10M	Post IPO	-	-	-	-
Oct 24, 2025	$2M	Post IPO	-	-	-	-
Jul 22, 2025	$1.04M	Post IPO	-	-	-	-

Access funding benchmarks and valuations. Sign up today!

View details of Celularity's funding rounds and investors

Celularity's employee count trend

Celularity has 145 employees as of Jun 26. Here is Celularity's employee count trend over the years:

Uncover Celularity's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Celularity include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Celularity, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, F-Prime Capital & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
16th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Sorrento Therapeutics & 8 others	71/100